Synairgen (SNG)

Sector:

Pharma and Biotech

Index:

FTSE AIM All-Share

0.70p
   
  • Change Today:
    -0.20p
  • 52 Week High: 5.46
  • 52 Week Low: 0.70
  • Currency: UK Pounds
  • Shares Issued: 1,102.66m
  • Volume: 498,868
  • Market Cap: £7.74m
  • RiskGrade: 510
  • Beta: 0.01

Synairgen Overview

In the 1970s, Synairgen founder, British immunophysician Professor Sir Stephen Holgate, began investigating how respiratory viruses can cause serious illness, with the aim of translating these insights into effective clinical treatments. Joined by fellow University of Southampton professors Donna Davies and Ratko Djukanovic in the 1990s, together the three formed Synairgen in 2003 with the sole aim of bringing these advances to patients.

1 Day Chart

1 Day Chart

6 Month Chart

6 Month Chart
Barclays logo

Digital Look Charts Sponsored by Barclays Stockbrokers

Financials

Latest F'cast
Div Yield 0.0% 0.0%
Div Cover n/a n/a
Op Mrgn n/a n/a
ROCE n/a  
Latest F'cast
P/E n/a n/a
PEG n/a n/a
Pr/Revenue n/a n/a
Pr/Book 0.8  
Latest F'cast
Revenue n/a n/a
PBT n/a n/a
EPS n/a n/a
DPS n/a n/a

Synairgen Fundamentals

Year Ending Revenue (£m) Pre-tax (£m) EPS P/E PEG EPS Grth. Div Yield
31-Dec-19 n/a (4.79) (2.55)p n/a n/a n/a n/a 0.0%
31-Dec-20 n/a (17.73) (6.84)p n/a n/a n/a n/a 0.0%
31-Dec-21 n/a (57.86) (17.55)p n/a n/a n/a n/a 0.0%
31-Dec-22 n/a (20.09) (6.33)p n/a n/a n/a n/a 0.0%
31-Dec-23 n/a (9.66) (3.02)p n/a n/a n/a n/a 0.0%

a. Based on UK GAAP presentation of accounts - includes discontinued activities

Synairgen Company Announcements

Result of General Meeting 28-Mar-2025 14:21 RNS
Proposed cancellation of trading on AIM 11-Mar-2025 07:00 RNS
Holding(s) in Company 17-Jan-2025 12:55 RNS

Synairgen ShareCast News

Synairgen names Joseph Colliver as CFO 11-Oct-2023 ShareCast
Synairgen posts positive results for phase 2 tri... 04-Oct-2022 ShareCast
Synairgen unveils positive clinical trial data 07-Sep-2022 ShareCast

Synairgen Top Newspaper Links

AstraZeneca buys the rights to an asthma treatme... 13-Jun-2014 Daily Mail
AstraZeneca in new £138million asthma drug deal 13-Jun-2014 Express & Star

Latest Synairgen Director Deals

No deals were found in the last 28 days.

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

Note 3: Above ratios are on a 'per annum' basis, adjusted for corporate actions and based on the fundamentals of the primary listed security.

Note 4: Under IFRS, all figures are based on 'Continuing' operations unless otherwise stated.

Note 5: In the case of dual listed securities, broker recommendations and forecasts relate to the primary listing.

Note 6: Forecast figures based on normalised accounts.

 

Synairgen Market Data

Currency UK Pounds
Share Price 0.70p
Change Today -0.20p
% Change -22.00 %
52 Week High 5.46
52 Week Low 0.70
Volume 498,868
Shares Issued 1,102.66m
Market Cap £7.74m
Beta 0.01
RiskGrade 510

Synairgen Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
47.55% above the market average47.55% above the market average47.55% above the market average47.55% above the market average47.55% above the market average
95.74% above the sector average95.74% above the sector average95.74% above the sector average95.74% above the sector average95.74% above the sector average
Price Trend
94.67% below the market average94.67% below the market average94.67% below the market average94.67% below the market average94.67% below the market average
87.76% below the sector average87.76% below the sector average87.76% below the sector average87.76% below the sector average87.76% below the sector average
Income Not Available
Growth Not Available

Synairgen Dividends

No dividends found

Trades for 31-Mar-2025

Time Volume / Share Price
11:16 50,000 @ 0.98p
11:11 1,100 @ 0.78p
10:53 100,000 @ 0.97p
10:53 1,995 @ 0.78p
10:52 85 @ 0.98p

Synairgen Key Personnel

CEO Richard J Marsden

Top of Page